

Poster presentation

## Factors related to low HDL-cholesterol in HIV-infected patients

S Puerta<sup>1</sup>, R Palacios\*<sup>1</sup>, F Orihuela<sup>2</sup>, J De la Torre<sup>3</sup>, S Fernandez<sup>4</sup>, M Grana<sup>5</sup>, J Rodan<sup>6</sup> and J Santos<sup>1</sup>

Address: <sup>1</sup>Hosp Virgen de la Victoria, Malaga, Spain, <sup>2</sup>Hosp Carlos Haya, Malaga, Spain, <sup>3</sup>Hosp Costa del Sol, Marbella, Spain, <sup>4</sup>Hosp de la Axarquía, Velez-Málaga, Spain, <sup>5</sup>Hosp de la Serranía, Ronda, Spain and <sup>6</sup>Hosp de Antequera, Antequera, Spain

\* Corresponding author

from Ninth International Congress on Drug Therapy in HIV Infection  
Glasgow, UK. 9–13 November 2008

Published: 10 November 2008

*Journal of the International AIDS Society* 2008, **11**(Suppl 1):P112 doi:10.1186/1758-2652-11-S1-P112

This abstract is available from: <http://www.jiasociety.org/content/11/S1/P112>

© 2008 Puerta et al; licensee BioMed Central Ltd.

### Purpose of the study

Low HDL-cholesterol (HDL-C) levels are associated with an increased risk of cardiovascular disease (CVD). The objective of this study was to investigate the prevalence of low HDL-C in HIV-infected patients and related factors.

### Methods

Multicenter, cross-sectional study of all HIV-infected patients on regular follow-up in five Andalusian hospitals (southern Spain) during March–August 2007. A questionnaire about cardiovascular risk factors (CVR) and a physical exam, including anthropometric parameters and blood pressure, were done in all cases. Recent fasting lab data ( $\leq 3$  prior months) were available in all cases, which included lipid profile, glycaemia, CD4 cells count, and HIV viral load. Statistical analysis: SPSS 11.0.

### Summary of results

Data are from 1,072 patients, 43.8% of whom had low HDL-C. The prevalence of low HDL-C was higher among patients diagnosed with AIDS than those without AIDS (47.7 vs. 41.1%;  $p = 0.037$ ), those not on ART than those who were on ART (53.4 vs. 42.5%;  $p = 0.01$ ), those with detectable HIV viral load (55.2 vs. 40.2%;  $p < 0.0001$ ), with CD4 cell counts  $\leq 350$  cells/ $\mu\text{L}$  (53.9 vs. 40.1%;  $p < 0.0001$ ), smokers than no smokers (46.8 vs. 38.8%;  $p = 0.014$ ), and those with hypertriglyceridemia (58.6 vs. 34.3%;  $p < 0.0001$ ). For patients on ART, the prevalence of low HDL-C was higher for those on PI than those taking NNRTI (52.1 vs. 31.4%;  $p < 0.0001$ ). In the multivariate analysis, the following factors remained significant:

tobacco use (OR 1.37, 95% CI 1.04–1.8;  $p = 0.04$ ), hypertriglyceridemia (OR 2.94, 95% CI 2.2–3.8;  $p < 0.00001$ ), CD4 cells count  $\leq 350$  cells/ $\mu\text{L}$  (OR 1.74, 95% CI 1.2–2.3;  $p < 0.0001$ ), and detectable HIV viral load (OR 1.85, 95% CI 1.3–2.5;  $p < 0.0001$ ).

### Conclusion

Immunological and virological situation, in addition to traditional cardiovascular risk factors such as tobacco and hypertriglyceridemia, affect HDL-C levels in HIV-infected patients. For patients on ART, the use of PI is associated with a higher probability of low levels of HDL-C. Although it is not clear if the higher HDL-C levels associated with ART use are surrogates for decreased CVD risk, this may be another reason to start ART earlier.